Anti-CV2 (IgG + IgA)

Optimal result: 0.1 – 10 Units

Anti CV2 antibodies are a group of antibodies that react with a 66 kd brain protein belonging to the family of CRMP proteins. The manifestations associated with anti CV2 antibodies include cerebellar degeneration, uveitis, and peripheral neuropathy, and mixed axonal and demyelinating peripheral neuropathy.

Anti-CV2 antibodies, encompassing both IgG and IgA immunoglobulin classes, target a neuronal protein known as CRMP-5 (Collapsin Response Mediator Protein 5). These antibodies are typically associated with paraneoplastic neurological syndromes (PNS), a group of disorders that arise from the immune system's response to certain cancers. The presence of anti-CV2 antibodies can lead to a variety of neurological manifestations, ranging from cerebellar ataxia, limbic encephalitis, to peripheral neuropathies, and less frequently, myelopathies.

Anti-CV2 antibodies, encompassing both IgG and IgA immunoglobulin classes, target a neuronal protein known as CRMP-5 (Collapsin Response Mediator Protein 5). These antibodies are typically associated with paraneoplastic neurological syndromes (PNS), a group of disorders that arise from the immune system's response to certain cancers. The presence of anti-CV2 antibodies can lead to a variety of neurological manifestations, ranging from cerebellar ataxia, limbic encephalitis, to peripheral neuropathies, and less frequently, myelopathies.

The detection of anti-CV2 antibodies is clinically significant for several reasons. Firstly, they are often indicative of an underlying malignancy, most commonly small cell lung cancer, thymoma, or other neuroendocrine tumors. Therefore, the presence of these antibodies can prompt a search for occult cancer in a patient presenting with neurological symptoms. Secondly, the type and severity of the neurological symptoms associated with anti-CV2 antibodies can vary widely among individuals, reflecting the diverse roles of CRMP-5 in the nervous system.

Additionally, the presence of anti-CV2 antibodies can influence the management and treatment of patients. Treatments may involve immunosuppressive therapies aimed at reducing the autoimmune response, as well as addressing the underlying tumor, if present. Monitoring the levels of these antibodies may provide insight into the response to treatment, although their levels do not always correlate with clinical improvement.

Moreover, the presence of both IgG and IgA anti-CV2 antibodies may have implications for the disease course, as different immunoglobulin classes can be associated with different pathogenic mechanisms and may affect the nervous system in distinct ways. This dual positivity can complicate the clinical picture but also provides a more comprehensive understanding of the patient's immune response.

In summary, anti-CV2 antibodies are important biomarkers for diagnosing and managing paraneoplastic neurological syndromes, guiding the search for underlying malignancies, and informing treatment strategies. Their detection calls for a multidisciplinary approach to patient care, involving oncologists, neurologists, and immunologists to address the complex interplay between the nervous system and cancer-related immune phenomena.

References:

Antoine JC, Honnorat J, Camdessanché JP, Magistris M, Absi L, Mosnier JF, Petiot P, Kopp N, Michel D. Paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy. Ann Neurol. 2001 Feb;49(2):214-21. doi: 10.1002/1531-8249(20010201)49:2<214::aid-ana41>3.0.co;2-w. PMID: 11220741.

Anti-CV2 (IgG + IgA)
Healthmatters dashboard showing biomarker trend graph

Every lab result you’ve ever had, charted and explained.

Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.

Start with my report →
Beyond Anti-CV2 (IgG + IgA) — 10,000+ markers explained
One Anti-CV2 (IgG + IgA) result tells you where you are. Your history tells you where you’re heading. Upload your past lab reports and see this marker — and every marker on them —every marker charted against your own lab’s ranges.
Start with this report →
Healthmatters timeline preview showing biomarker trends over time
Clinical Sources & References

All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.

Article Review Log
Written by Healthmatters Editorial Team
Healthmatters Lifetime Plan

Pay $250. Track your health forever

One payment. No renewals. Yours for life.

10,000+ biomarkers explained · trends over time

See other plans →
Secure checkout via Stripe · GDPR & HIPAA
We accept results from any lab
LabCorp Quest Diagnostics Genova Diagnostics DUTCH Test Doctor's Data Vibrant America ZRT Laboratory Cyrex Labs + any other lab

What members are saying

★★★★★ 10,000+ happy members
★★★★★

"Watching my numbers move over the years — instead of forgetting last time's results — completely changed how I manage my health."

Daniel
Member since 2022
★★★★★

"Living across several countries made keeping my lab results organized a real challenge. Healthmatters brought my results from the USA, Spain, and Germany together — 20 years of history, with long-term trends instead of scattered reports."

Ben
Member since 2021 · tracks across countries
★★★★★

"Standard lab ranges are too wide for how I practice — 'normal' isn't optimal. I set my own bands, so a client sees yellow before a marker goes officially out of range. That's the conversation I want to be having."

Dr. Alexandra
Functional medicine · 6 yrs on Pro